Amplyx Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Amplyx Pharmaceuticals, Inc. - overview
Established
2006
Location
San Diego, CA, US
Primary Industry
Pharmaceuticals
About
Founded in 2006 and based in California, US, Amplyx Pharmaceuticals, Inc. operates as a developer of small molecule drugs for the treatment of oncology and infectious diseases. The company was founded by Andre Marquis, Gerald Crabtree and Mitchell Mutz. In May 2020, Amplyx Pharmaceuticals, Inc.
raised USD 53 million in series C funding led by returning investor Sofinnova Ventures and in April 2021, Amplyx Pharmaceuticals, Inc. was acquired by Pfizer Inc. Amplyx Pharmaceuticals develops small molecule drugs with enhanced efficacy and lower toxicity by adding a second small molecule to an existing drug. Amplyx drug development pipeline has three product candidates under clinical development called fosmanogepix, APX2039 and MAU868.
Fosmanogepix is a novel broad-spectrum antifungal agent being evaluated in Phase 2 clinical trials in patients with life-threatening fungal infections caused by aspergillosis and candidemia. MAU868 is a monoclonal antibody used for the treatment of clinically significant BK virus infection in people who have received either a kidney or hematopoietic cell transplant. The company’s future strategy includes advancing the clinical development of its product candidates.
Current Investors
New Enterprise Associates, Sofinnova Investments, Pappas Capital
Primary Industry
Pharmaceuticals
Sub Industries
Epidemiology, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.amplyx.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Amplyx Pharmaceuticals, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.